NKGen Biotech Inc (Nasdaq:NKGN), a developer of autologous and allogeneic natural killer (NK) cell therapeutics, announced on Wednesday that it has been granted Fast Track designation by the US Food and Drug Administration (FDA) for its autologous NK cell therapy, troculeucel, for moderate Alzheimer's disease (AD).
This designation accelerates the development and review process for therapies addressing serious health conditions and unmet medical needs.
With Fast Track status, NKGen benefits from increased FDA interactions and enhanced visibility, potentially qualifying for Accelerated Approval, Priority Review and Rolling Review, streamlining the path to market.
NKGen is currently enrolling patients in a Phase 2a trial for moderate AD and plans to release updated clinical data by the end of 2025.
Immunome initiates Phase 1 trial of ROR1-targeted ADC IM-1021
Arrowhead Pharmaceuticals reports positive topline results for ARO-C3 in IgA nephropathy trial
Celltrion's OMLYCLO receives US FDA approval
RiboX Therapeutics doses first patient in RXRG001 first-in-human Phase I/IIa clinical trial
Doer Bio completes DR10624phase two clinical study enrolment
Health Canada approves ALK's ACARIZAX for young children with dust mite allergy
Kancera and Recardio sign letter of intent for licensing agreement
Bantam Pharmaceutical expands Phase 1 trial of BTM-3566 into Canada
Integral Molecular reports first patient dosed in CTIM-76 Phase 1 clinical trial
Plus Therapeutics secures FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda
CStone Pharmaceuticals submits Phase Ib clinical trial application for CS5001 in Australia
Akeso completes patient enrolment for cadonilimab Phase III registrational clinical trial
Jazz Pharmaceuticals to acquire Chimerix in USD935m deal to expand oncology portfolio